Kimberly-Clark prepares concessions to gain EU approval for Kenvue deal - report (KVUE:NYSE)

Kimberly-Clark (KMB) shares rose 2.5% after announcing adjustments to address EU antitrust concerns over its $40B Kenvue (KVUE) acquisition. The EU decision deadline is September 29. KMB offers a 5.09% dividend yield but has a high payout ratio of 0.89, raising sustainability concerns. Its GF Value™ suggests the stock is 18.8% undervalued, with a GF Score™ of 72/100.

Kimberly-Clark (KMB) is preparing asset sales to address EU antitrust concerns over its $40B acquisition of Kenvue (KVUE). The EU is expected to formally raise concerns this week. Shares of both companies rose on the news. The deal, announced last November, would expand Kimberly-Clark's product portfolio. The EU has until September 29 for a preliminary review.

Kenvue (KVUE) is highlighted as a strong high-yield dividend stock with a 4.68% yield and 64 years of consecutive dividend increases. Its stable of well-known brands reported Q2 revenue of $3.95B and EPS of $0.24. The company is being acquired by Kimberly-Clark (KMB), another Dividend King, which may create uncertainty about Kenvue's dividend.

Kimberly-Clark is preparing asset sales to address EU antitrust concerns regarding its $40 billion acquisition of Kenvue. The European Commission is expected to formally raise its concerns this week. Kimberly-Clark shares rose 2.7% and Kenvue gained 2.3% on the news. The deal, announced in November, would expand Kimberly-Clark's product range to include Kenvue's brands like Listerine, Aveeno, and Neutrogena.

Kimberly-Clark negotiates EU regulators for $40B Kenvue acquisition, offering concessions. Definium Therapeutics' LSD-based drug reduced anxiety in trials. Scholar Rock's SMA drug priced at $11,659 per vial. Electra Therapeutics targets $977.6M IPO valuation. BioNTech's lung cancer treatment shows trial success.

Kimberly-Clark (KMB) is preparing asset sales to address EU antitrust concerns regarding its $40 billion acquisition of Kenvue. The EU is expected to formally raise its concerns this week, with Kimberly-Clark facing a September 29 deadline to submit concessions or face a full investigation. The deal has already received conditional approval in Australia and South Africa.